Egyptian fruit bats (Rousettus aegyptiacus) were inoculated subcutaneously (n = 22) with Marburg virus (MARV). No deaths, overt signs of morbidity, or gross lesions was identified, but microscopic pathological changes were seen in the liver of infected bats. The virus was detected in 15 different tissues and plasma but only sporadically in mucosal swab samples, urine, and fecal samples. Neither seroconversion nor viremia could be demonstrated in any of the in-contact susceptible bats (n = 14) up to 42 days after exposure to infected bats. In bats rechallenged (n = 4) on day 48 after infection, there was no viremia, and the virus could not be isolated from any of the tissues tested. This study confirmed that infection profiles are consistent with MARV replication in a reservoir host but failed to demonstrate MARV transmission through direct physical contact or indirectly via air. Bats develop strong protective immunity after infection with MARV.
Novel whole virus vaccine offers promising protection against Ebola infection
A study published in Science demonstrates that vaccination with a mutated form of the Ebola virus provides some measure of protection to non-human primates. This finding places the vaccine one step closer to clinical trials in humans.
The researchers publishing this study have developed what’s called a “whole virus” vaccine for Ebola. Viruses have proteins on their exterior and genetic material on their interior. Whole virus vaccines present the host’s immune system with multiple viral proteins and the viral genetic material. These vaccines trigger broader immune system responses than vaccines that only present a single protein from the virus. Whole virus vaccines have had widespread success in offering protection against potentially deadly diseases such as smallpox, measles, and influenza.
Ed Rybicki's insight:
NOW everyone starts getting Ebola results...never mind, it'll be along again shortly - like flu.
The cure to cancer could come from researchers at the Duke University Hospital Cancer Center.
Duke Medicine’s Dr. Matthias Gromeier has been working on a Glioblastoma treatment using a modified polio virus for more than 25-years.
Now, Duke researchers are testing the treatment and trials show it is working for some patients.
After doctors told Clara Guy she had six to 18-months to live, she transferred to Duke Medicine’s Preston Robert Tisch Brain Tumor Center, where she became a stage four Glioblastoma research patient. Glioblastoma is an aggressive and fast growing type of brain cancer.
"It's a big word...Glioblastoma is so much than a four letter word, and it really ought to be,” she said.
Guy was under the regulate vaccine trial.
"It turns your immune system onto high gear to teach it to fight the cancer cells,” she said.
Neurooncologist Dr. Annick Desjardins is using the genetically modified polio virus as treatment for some patients during Phase One of the research.
An experimental Ebola vaccine tested on humans in Europe and Africa sparks the production of the antibodies needed to neutralize the deadly virus, a Geneva hospital said Wednesday.
Initial clinical trials of the VSV-ZEBOV candidate vaccine, manufactured by the Public Health Agency of Canada and developed by Merck, show that it "triggers the production of antibodies capable of neutralizing the Ebola virus," the Geneva University Hospitals (HUG) said in a statement.
West Africa's Ebola outbreak could be stanched by mid-year – but in the epidemic's wake, another public health crisis looms. Disruption of the region's already feeble health care systems has derailed health campaigns targeting childhood diseases, leaving the door wide open for measles and other preventable illnesses.
President Yahyah Jammeh, the dictator who has defied medical opinion since 2007 by claiming to have found a cure for HIV-AIDS, has found allies in a British homoeopathic group sponsored by the official suppliers of homoeopathic medicine to the Royal...
The world can beat the liver-attacking hepatitis B virus, which results in some 650.000 deaths a year, the World Health Organization said Thursday, releasing its first treatment guidelines for the disease.
Scientists have found evidence that a polio-like virus called EV-D68 is behind a mysterious outbreak of paralysis in children [in the USA] last year.
LAST YEAR, HUNDREDS of children across the country got sick with what looked like a common cold. Nothing to worry about: body aches, runny nose, coughing and sneezing. But then, mysteriously, a handful of those kids became paralyzed—first, just in an arm or a leg, and then spreading so far that some children needed a ventilator to breathe. The CDC reports that since August 2014, at least 115 children in 34 states have developed unexplained muscle weakness or paralysis, which they’re now calling acute flaccid myelitis. Doctors have urgently been hunting down the origin of this strange illness for over half a year, and now they think they’ve finally identified the culprit: enterovirus D68.
TWIN FALLS • A major disease threat to winter wheat and barley has appeared in fields across southern Idaho.
Barley yellow dwarf virus “is rampant from Parma to Ririe,” said Juliet Marshall, a University of Idaho Extension cereal pathologist in Idaho Falls. Some growers are killing infected fields and reseeding with other crops.
Ed Rybicki's insight:
Ah, BYDV...back to my roots of 31 years ago, when I published a paper and a thesis on BYDV in SOuth African small grains. It's never gone away.
Sunday marked a year into the largest Ebola outbreak in history. It has been, and continues to be, a cruel lesson in bureaucratic ineptitude and “First World” disregard for Africans, yet it has also been a year when Africans and Westerners alike have shown fidelity by staring real horror in the face. As Medecins Sans Frontieres (Doctors Without Borders) international president, Dr Joanne Liu, said in an appeal to UN member states in September: ‘To put out this fire, we must run into the burning building.’
Viruses and other selfish genetic elements are dominant entities in the biosphere, with respect to both physical abundance and genetic diversity. Various selfish elements parasitize on all cellular life forms. The relative abundances of different classes of viruses are dramatically different between prokaryotes and eukaryotes. In prokaryotes, the great majority of viruses possess double-stranded (ds) DNA genomes, with a substantial minority of single-stranded (ss) DNA viruses and only limited presence of RNA viruses. In contrast, in eukaryotes, RNA viruses account for the majority of the virome diversity although ssDNA and dsDNA viruses are common as well. Phylogenomic analysis yields tangible clues for the origins of major classes of eukaryotic viruses and in particular their likely roots in prokaryotes. Specifically, the ancestral genome of positive-strand RNA viruses of eukaryotes might have been assembled de novo from genes derived from prokaryotic retroelements and bacteria although a primordial origin of this class of viruses cannot be ruled out. Different groups of double-stranded RNA viruses derive either from dsRNA bacteriophages or from positive-strand RNA viruses. The eukaryotic ssDNA viruses apparently evolved via a fusion of genes from prokaryotic rolling circle-replicating plasmids and positive-strand RNA viruses. Different families of eukaryotic dsDNA viruses appear to have originated from specific groups of bacteriophages on at least two independent occasions. Polintons, the largest known eukaryotic transposons, predicted to also form virus particles, most likely, were the evolutionary intermediates between bacterial tectiviruses and several groups of eukaryotic dsDNA viruses including the proposed order “Megavirales” that unites diverse families of large and giant viruses. Strikingly, evolution of all classes of eukaryotic viruses appears to have involved fusion between structural and replicative gene modules derived from different sources along with additional acquisitions of diverse genes.
Graphic by Ed Rybicki
Ed Rybicki's insight:
Wow...! A tour de force. Quite simply, says it all. REALLY nice piece of work!! And of course, they back me up in my view of how ss(-)RNA viruses evolved. Again B-)
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.